| Literature DB >> 26472105 |
Guang-Zhi Jin1, Wei Dong1, Hui Dong1, Hua Yu1, Jia Chen1, Wen-Long Yu2, Ai-Jun Li3, Wen-Ming Cong1, Meng-Chao Wu4.
Abstract
Myeloid-related protein 8 (MRP8) and 14 (MRP14) are abundantly expressed in several kinds of benign and malignant tumors. However, little is known about their clinicopathological significance in intrahepatic cholangiocarcinoma (ICC), biliary intraepithelial neoplasia (BilIN), intraductal papillary neoplasm of bile duct (IPNB), or inflammatory hepatic biliary ducts epithelium (IHBD). This study aimed to investigate the diagnostic and prognostic values of MRP8 and MRP14 as new biomarkers for ICC. We examined MRP8 and MRP14 expression levels by immunohistochemistry in IHBD (n = 15), BilIN (BilIN1 = 24, BilIN2 = 9, BilIN3 = 5), IPNB (n = 18) and ICC (n = 416). The differential diagnostic and prognosis values were also evaluated. The results showed that the ratio of tumor-infiltrating MRP8 and MRP14 positive immune cells, relative to biliary epithelial cells, was significantly increased in ICC tissues compared with nonmalignant tissues, including IHBD, BilIN1, BilIN2, BilIN3, and IPNB (P value < 0.05). In addition, over-expression levels of MRP8 and MRP14 were correlated with overall survival (OS) and time to recurrence (TTR) by univariate analysis; MRP8/MRP14 combination was an independent prognostic factor for OS and TTR. MRP8 and MRP14 expression might help to identify the benign bile duct diseases from ICC, as high expression of MRP8 and MRP14 suggests a poor prognosis after surgical resection.Entities:
Keywords: intrahepatic cholangiocarcinoma; myeloid-related protein 14; myeloid-related protein 8; prognosis; tumor-infiltrating immune cell
Mesh:
Substances:
Year: 2015 PMID: 26472105 PMCID: PMC4770777 DOI: 10.18632/oncotarget.5329
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Expression of MRP8 and MRP14 in IHBD, BilIN1, BilIN2, BilIN3, IPNB, ICC
H&E staining section shows histopathology of IHBD (A), BilIN1 (D), BinIN2 (G), BinIN3 (J), IPNB (M), ICC (P); MRP8 staining shown in IHBD (B), BilIN1 (E), BinIN2 (H), BinIN3 (K), IPNB (N), ICC (Q); MRP14 staining shown in IHBD (C), BilIN1 (F), BinIN2 (I), BinIN3 (L), IPNB (O), ICC (R) (200× magnification).
Figure 2The MRP8 and MRP14 expression level in IHBD, BilIN1, BilIN2, BilIN3, IPNB, ICC and the ROC curve
A scatter plot of MRP8 A. and MRP14 B. positive cells to the total number of biliary epithelial cells was obtained from the TMAs. Mann-Whitney test showed a significant difference between ICC and IHBD, BilIN1, BilIN2, BilIN3, IPNB. ROC curve analyses and AUC showed that MRP8 C. and MRP14 D. have good performance to distinguish ICC from IHBD, BilIN1, BilIN2, BilIN3, IPNB.
Figure 3Kaplan-Meier curves of OS and TTR differences among ICC patients in combined primary and testing cohorts
MRP8 combined with MRP14 A. and B. was found to be significant for both OS and TTR (by the log-rank test).
Univariate and multivariate analyses of factors associated with OS and TTR in combined primary and testing cohorts
| Factors | OS | TTR | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | HR | Multivariate 95% Cl | Univariate | HR | Multivariate 95% Cl | |||
| Age: ≤53 | 0.719 | 0.100 | ||||||
| Sex: male | 0.946 | 0.310 | ||||||
| Liver cirrhosis: no | 0.360 | 0.732 | 0.558–0.961 | |||||
| HBsAg: negative | 0.071 | 0.079 | ||||||
| Serum AFP, μg/L: ≤low | 1.336 | 1.039–1.717 | 0.054 | |||||
| Serum CEA, μg/L: ≤low | 1.696 | 1.272–2.262 | 1.596 | 1.138–2.235 | ||||
| Serum CA199, U/ml: ≤low | ||||||||
| Serum ALB, g/L: ≤low | 0.565 | 0.413–0.773 | 0.236 | |||||
| Serum GGT, U/L: ≤low | ||||||||
| Serum ALT, U/L: ≤low | 0.247 | |||||||
| Serum ALP, U/L: ≤low | 1.462 | 1.153–1.853 | ||||||
| Tumor size, cm: ≤low | 1.734 | 1.300–2.313 | 1.752 | 1.222–2.511 | ||||
| Tumor number: single | 1.499 | 1.133–1.983 | 1.563 | 1.185–2.063 | ||||
| Micro-vascular invasion: no | ||||||||
| TNM: I vs. II | 1.200 | 1.067–1.350 | 1.130 | 1.008–1.268 | ||||
| MRP8 number: ≤low | ||||||||
| MRP8 ratio: ≤low | 1.584 | 1.076–2.333 | ||||||
| MRP14 number: ≤low | ||||||||
| MRP14 ratio: ≤low | ||||||||
| MRP8 ratio/MRP14 ratio combination: all low vs. at least one high | 1.740 | 1.137–2.662 | ||||||
Note: OS, overall survival; TTR, time to recurrence; Cl, confidence interval; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; CEA, carcino embryonic antigen; CA199, carbohydrate antigen 19-9; ALB, albumin; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; TB, total bilirubin; ALT, alanine transaminase; TNM, tumor-nodes-metastases.